Vous avez cherché: doksorubicinom (Croate - Anglais)

docetaksel u kombinaciji s doksorubicinom
docetaxel in combination with doxorubicin

docetaxel kabi u kombinaciji s doksorubicinom
docetaxel kabi in combination with doxorubicin

docetaxel winthrop u kombinaciji s doksorubicinom
docetaxel winthrop in combination with doxorubicin

kombinirano liječenje s pegiliranim liposomalnim doksorubicinom
combination therapy with pegylated liposomal doxorubicin

258 bolesnika koji su primali docetaksel u kombinaciji s doksorubicinom,
258 patients who received docetaxel in combination with doxorubicin.

docetaksel u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
docetaxel in combination with doxorubicin and cyclophosphamide: adjuvant therapy

docetaxel kabi u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
docetaxel kabi in combination with doxorubicin and cyclophosphamide: adjuvant therapy

docetaxel winthrop u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
docetaxel winthrop in combination with doxorubicin and cyclophosphamide: adjuvant therapy

nije primijećena farmakokinetička interakcija u bolesnika prilikom kombiniranja vinflunina s doksorubicinom.
no pharmacokinetic interaction was observed in patients when vinflunine was combined with doxorubicin.

nakon adjuvantne kemoterapije doksorubicinom i ciklofosfamidom u kombinaciji s paklitakselom ili docetakselom.
following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.

taxespira u kombinaciji s doksorubicinom i ciklofosfamidom indiciran je za adjuvantno liječenje bolesnika s:
taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

cijepljenje živim cjepivom treba izbjegavati u bolesnika koji primaju olaratumab u kombinaciji s doksorubicinom.
vaccination with a live vaccine should be avoided in patients receiving olaratumab in combination with doxorubicin.

docetaxel accord u kombinaciji s doksorubicinom i ciklofosfamidom indiciran je za adjuvantno liječenje bolesnika s:
docetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

dio ispitivanja faze 2 bilo je randomizirano, otvoreno ispitivanje olaratumaba plus doksorubicina u odnosu na liječenje samo doksorubicinom.
the phase 2 portion of the study was a randomised, open label study of olaratumab plus doxorubicin versus doxorubicin alone.

za liječenje uznapredovalog karcinoma dojke, docetaxel se primjenjuje sam ili u kombinaciji s doksorubicinom, trastuzumabom ili kapecitabinom.
for the treatment of advanced breast cancer, docetaxel could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine.

deksametazon nema klinički značajnu farmakokinetičku interakciju s talidomidom, lenalidomidom, pomalidomidom, bortezomibom, vinkristinom ili doksorubicinom.
dexamethasone has no clinically significant pharmacokinetic interaction with thalidomide, lenalidomide, pomalidomide, bortezomib, vincristine or doxorubicin.

kada se bortezomib sun daje zajedno s pegiliranim liposomalnim doksorubicinom, bortezomib sun ćete primiti u venu ili potkožno u ciklusu liječenja koji traje 21 dan.
when bortezomib sun is given together with pegylated liposomal doxorubicin, you will receive bortezomib sun intravenously or subcutaneously as a 21-day treatment cycle.

ako vam prethodno nije liječen limfom plaštenih stanica velcade ćete primiti u venu zajedno s lijekovima rituksimabom, ciklofosfamidom, doksorubicinom i prednizonom.
if you have not been treated before for mantle cell lymphoma you will receive velcade intravenously together with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone.

ako vam prethodno nije liječen limfom plaštenih stanica bortezomib ćete primiti u venu ili potkožno zajedno s lijekovima rituksimabom, ciklofosfamidom, doksorubicinom i prednizonom.
if you have not been treated before for mantle cell lymphoma, you will receive bortezomib intravenously or subcutaneously together with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone.

lartruvo se daje u kombinaciji s doksorubicinom do 8 ciklusa liječenja, a nakon toga, u bolesnika kojima se bolest nije pogoršala, primjenjuje se samo lartruvo.
lartruvo is given in combination with doxorubicin for up to 8 cycles of treatment, followed by lartruvo alone in patients whose disease has not got worse.